Summary & Overview
HCPCS Level II J8520: Capecitabine, Oral, 150 mg
HCPCS Level II code J8520 denotes capecitabine, oral, 150 mg, an oral antineoplastic agent commonly prescribed in oncology care. Nationally, accurate use of this HCPCS Level II code supports correct claims submission for outpatient pharmacy dispensing and clinic-provided oral chemotherapy, which affects reimbursement, patient cost-sharing, and supply chain reporting. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find concise benchmarks and operational guidance on coding and billing workflows related to oral chemotherapy dispensing, an overview of payer coverage patterns and common modifier usage, and clinical context about capecitabine as an oral antineoplastic. The publication summarizes standard billing practices, highlights documentation elements typically required by major payers, and outlines areas where policy updates or payer-specific rules commonly affect claim adjudication. Data not available in the input is noted where applicable, and the report is intended for coding, billing, and revenue integrity teams seeking a national-level reference for J8520.
Billing Code Overview
HCPCS Level II code J8520 represents capecitabine, oral, 150 mg. This code is used to report dispensed oral chemotherapy tablets of capecitabine in the 150 mg strength. The service type is oral antineoplastic (chemotherapy) medication. The typical site of service for billing this code is outpatient pharmacy dispensing or an outpatient clinic where oral oncology drugs are provided to the patient.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a documented diagnosis of metastatic or adjuvant colorectal cancer, metastatic breast cancer, gastric cancer, or other malignancies for which oral capecitabine is indicated. The patient receives a prescription for J8520 (capecitabine, oral, 150 mg) from an oncologist during an outpatient oncology clinic visit. The clinical workflow includes: medication reconciliation and verification of prior chemotherapy regimens; patient education on dosing schedule (typically twice daily with food), potential toxicities (hand-foot syndrome, diarrhea, myelosuppression), and supportive care measures; baseline labs ordered (CBC, CMP) before initiation and at regular intervals; prescription submission to the specialty pharmacy or in-office dispensing; documentation of informed consent and indication in the medical record; and periodic follow-up visits for toxicity assessment, dose adjustments, and refill authorization. Administration is oral at home, with the clinic responsible for monitoring, toxicity management, and infusion- or clinic-based procedures only if complications arise.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Normal processing | Use when services are performed under usual circumstances without unusual effort; rarely applied to drugs but may appear on associated evaluation services. |